UNIV OF IOWA CALGB INSTITUTIONAL GRANT

描述(改编自申请人的摘要)：本申请书为 继续爱荷华大学参与癌症和癌症研究 B组白血病我们未来5年的目标将包括：(1) 维持每年100多名患者的临床试验应计费用(2) 在CALGB方案中增加下列领域的新研究：(A)紫苏的使用 酒精作为RAS的抑制剂既具有抗肿瘤作用，又具有抗肿瘤的作用 与其他药物结合，并可能作为化学预防药物，(B) 慢性阻塞性肺疾病患者外周血中RAS基因突变的检测 化疗是乳腺癌的一种辅助手段，并有可能导致 骨髓增生异常综合征和白血病，(C)omega 3的进一步试验 脂肪酸作为癌症恶病质的治疗方法和治疗的辅助手段 癌症，(D)继续开发3期和4期的综合治疗方案 非小细胞肺癌。尤其值得一提的是，密歇根大学的一名飞行员 爱荷华州吉西他滨/卡铂治疗非小细胞肺癌或能 帮助CALGB在未来(3)将CALGB试验扩大到农村医院 爱荷华州爱荷华州大学的内科医生正在提供肿瘤学治疗 (爱荷华州华盛顿；爱荷华州Keosauqua；爱荷华州迪布克；爱荷华州马斯卡廷； 爱荷华州费尔菲尔德；爱荷华州麦迪逊堡)

DESCRIPTION (adapted from the applicant's abstract): This application is to continue the University of Iowa participation in studies of Cancer and Leukemia Group B. Our goals over the next 5 year period will include: (1) maintenance of accrual to clinical trials of over 100 patients per year (2) add new studies to the CALGB program in the area of: (a) use of Perillyl alcohol as an inhibitor of RAS function both as an antineoplastic in combination with other agents and possibly as a chemopreventive agent, (b) assessment of RAS mutations in the peripheral blood of women who have had chemotherapy as an adjuvant for breast cancer and would be at risk for myelodysplastic syndrome and leukemia, (c) further trials of omega three fatty acids as therapy for cancer cachexia and as an adjuvant to therapy in cancer, (d) continue to develop combined modality therapy for stage 3 and 4 non-small cell lung cancer. In particularly, a pilot at the University of Iowa of Gemcitabine/Carboplatin for non-small cell lung cancer may be able to help CALGB in the future (3) expand CALGB trials to rural hospitals in Iowa where University of Iowa physicians are now providing oncology care (Washington, Iowa; Keosauqua, Iowa; Dubuque, Iowa; Muscatine, Iowa; Fairfield, Iowa; Fort Madison, Iowa)